The biotech company T3 Pharmaceuticals, a spin-off from the University of Basel, is being acquired by the German pharmaceutical company Boehringer Ingelheim. T3 Pharma has developed a novel technology that uses live bacteria to deliver therapeutic proteins to cancer cells and the tumor microenvironment.
